These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 35861622)

  • 21. Development and confirmation of potential gene classifiers of human clear cell renal cell carcinoma using next-generation RNA sequencing.
    Eikrem OS; Strauss P; Beisland C; Scherer A; Landolt L; Flatberg A; Leh S; Beisvag V; Skogstrand T; Hjelle K; Shresta A; Marti HP
    Scand J Urol; 2016 Dec; 50(6):452-462. PubMed ID: 27739342
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Statistical methods for analyzing tissue microarray data.
    Liu X; Minin V; Huang Y; Seligson DB; Horvath S
    J Biopharm Stat; 2004 Aug; 14(3):671-85. PubMed ID: 15468758
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Role of the Pathologist in Renal Cell Carcinoma Management.
    Matar S; El Ahmar N; Laimon YN; Ghandour F; Signoretti S
    Hematol Oncol Clin North Am; 2023 Oct; 37(5):849-862. PubMed ID: 37258353
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combining epigenetic and clinicopathological variables improves specificity in prognostic prediction in clear cell renal cell carcinoma.
    Andersson-Evelönn E; Vidman L; Källberg D; Landfors M; Liu X; Ljungberg B; Hultdin M; Rydén P; Degerman S
    J Transl Med; 2020 Nov; 18(1):435. PubMed ID: 33187526
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The genomics of renal cell carcinoma and its role in renal mass biopsy.
    Salami SS; George AK; Udager AM
    Curr Opin Urol; 2018 Jul; 28(4):383-391. PubMed ID: 29708949
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A decade of pharmacogenomics research on tyrosine kinase inhibitors in metastatic renal cell cancer: a systematic review.
    Diekstra MH; Swen JJ; Gelderblom H; Guchelaar HJ
    Expert Rev Mol Diagn; 2016; 16(5):605-18. PubMed ID: 26837796
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Individualizing renal cell carcinoma treatment through biomarkers discovery in the era of immune checkpoint inhibitors: where do we stand?
    Porta C; Cosmai L; Rizzo M
    Curr Opin Urol; 2021 May; 31(3):236-241. PubMed ID: 33742982
    [TBL] [Abstract][Full Text] [Related]  

  • 28.
    Lin W; Chen X; Chen T; Liu J; Ye Y; Chen L; Qiu X; Chia-Hsien Cheng J; Zhang L; Wu J; Qiu S
    DNA Cell Biol; 2020 Jun; 39(6):1000-1011. PubMed ID: 32282241
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adjuvant Therapy Options in Renal Cell Carcinoma: Where Do We Stand?
    Martinez Chanza N; Tripathi A; Harshman LC
    Curr Treat Options Oncol; 2019 May; 20(5):44. PubMed ID: 31054006
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Restricted mean survival time: Does covariate adjustment improve precision in randomized clinical trials?
    Karrison T; Kocherginsky M
    Clin Trials; 2018 Apr; 15(2):178-188. PubMed ID: 29502444
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Novel biomarkers in renal cell carcinoma. Identification and functional characterization].
    Macher-Göppinger S
    Pathologe; 2015 Nov; 36 Suppl 2():201-4. PubMed ID: 26362327
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low CCL-21 expression associates with unfavorable postoperative prognosis of patients with metastatic renal cell carcinoma.
    Xiong Y; Liu L; Wang J; Xi W; Xia Y; Bai Q; Qu Y; Long Q; Xu J; Guo J
    Oncotarget; 2017 Apr; 8(15):25650-25659. PubMed ID: 27783999
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Power estimation in biomarker studies where events are already observed.
    Polley MC
    Clin Trials; 2017 Dec; 14(6):621-628. PubMed ID: 28776405
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study.
    Voss MH; Reising A; Cheng Y; Patel P; Marker M; Kuo F; Chan TA; Choueiri TK; Hsieh JJ; Hakimi AA; Motzer RJ
    Lancet Oncol; 2018 Dec; 19(12):1688-1698. PubMed ID: 30416077
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genetic pathways involved in carcinogenesis of clear cell renal cell carcinoma: genomics towards personalized medicine.
    Audenet F; Yates DR; Cancel-Tassin G; Cussenot O; Rouprêt M
    BJU Int; 2012 Jun; 109(12):1864-70. PubMed ID: 22035299
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of a prognostic risk model for clear cell renal cell carcinoma by systematic evaluation of DNA methylation markers.
    Joosten SC; Odeh SNO; Koch A; Buekers N; Aarts MJB; Baldewijns MMLL; Van Neste L; van Kuijk S; Schouten LJ; van den Brandt PA; Tjan-Heijnen VC; van Engeland M; Smits KM
    Clin Epigenetics; 2021 May; 13(1):103. PubMed ID: 33947447
    [TBL] [Abstract][Full Text] [Related]  

  • 37. circCHST15 is a novel prognostic biomarker that promotes clear cell renal cell carcinoma cell proliferation and metastasis through the miR-125a-5p/EIF4EBP1 axis.
    Gui CP; Liao B; Luo CG; Chen YH; Tan L; Tang YM; Li JY; Hou Y; Song HD; Lin HS; Xu QH; Yao GS; Yao HH; Xi-Liu ; Luo JH; Cao JZ; Wei JH
    Mol Cancer; 2021 Dec; 20(1):169. PubMed ID: 34922539
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The emerging role of extracellular vesicles as biomarkers for urogenital cancers.
    Nawaz M; Camussi G; Valadi H; Nazarenko I; Ekström K; Wang X; Principe S; Shah N; Ashraf NM; Fatima F; Neder L; Kislinger T
    Nat Rev Urol; 2014 Dec; 11(12):688-701. PubMed ID: 25403245
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nonparametric inference of complier quantile treatment effects in randomized trials with imperfect compliance.
    Mao L
    Biostat Epidemiol; 2022; 6(2):249-265. PubMed ID: 37551295
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current and future strategies in nonclear-cell metastatic renal cell carcinoma.
    Albiges L; Escudier B
    Curr Opin Urol; 2015 Sep; 25(5):367-73. PubMed ID: 26153638
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.